ArticleiScience2026
Pharmacogenomic diversity among Arab populations: A systematic review.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association ofFrontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenomics enables precision pharmacotherapy by linking genetic variation to drug response, yet Arab populations are underrepresented in global reference datasets. We systematically synthesized pharmacogenomic allele-frequency evidence across Arab countries, focusing on clinically actionable genes, to describe population variation, identify high-priority variants, and highlight research gaps. We analyzed 295 studies including 94,346 individuals from 19 countries, pooled country-level allele counts for frequently tested variants, and compared pooled estimates with Middle Eastern reference frequencies. Across most loci, allele-frequency profiles were broadly similar between countries, but several variants showed marked, locus-specific differences with direct relevance to anticoagulants, statins, thiopurines, antidepressants, and fluoropyrimidines. Evidence was uneven across countries and often limited by inconsistent genotyping and incomplete reporting of haplotypes and structural variation. These findings support variant-focused implementation, underscore the need for better population coverage and standardized reporting, and motivate development of a regional pharmacogenomics resource to improve the safety and effectiveness of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.